Perspective Therapeutics (NYSE:CATX) Sees Unusually-High Trading Volume – Here’s Why

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) saw unusually-high trading volume on Monday . Approximately 307,892 shares changed hands during mid-day trading, a decline of 55% from the previous session’s volume of 682,754 shares.The stock last traded at $12.59 and had previously closed at $12.66.

Wall Street Analyst Weigh In

CATX has been the subject of a number of recent research reports. Oppenheimer restated an “outperform” rating and set a $22.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 11th. Royal Bank of Canada cut their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Wedbush assumed coverage on shares of Perspective Therapeutics in a research note on Tuesday, October 1st. They issued an “outperform” rating and a $25.00 target price for the company. Bank of America assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $21.43.

Perspective Therapeutics Trading Up 1.9 %

The firm’s 50 day simple moving average is $13.83.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. On average, equities analysts expect that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Sykon Capital LLC grew its stake in Perspective Therapeutics by 4.7% during the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics during the second quarter valued at about $118,000. SG Americas Securities LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth approximately $246,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Perspective Therapeutics in the second quarter worth $188,000. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.